rs104893737
Variant summary
Our verdict is Pathogenic. The variant received 12 ACMG points: 12P and 0B. PVS1PM2PP5_Moderate
The NM_023067.4(FOXL2):c.157C>T(p.Gln53*) variant causes a stop gained change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★).
Frequency
Consequence
NM_023067.4 stop_gained
Scores
Clinical Significance
Conservation
Publications
- blepharophimosis, ptosis, and epicanthus inversus syndromeInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), G2P
- premature ovarian failure 3Inheritance: Unknown Classification: LIMITED Submitted by: Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 12 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
not provided Pathogenic:1
The Q53X variant in the FOXL2 gene has been reported previously in association with blepharophimosis-ptosis-epicanthus inversus syndrome (Ramirez-Castro et al., 2002). This variant is predicted to cause loss of normal protein function through protein truncation, as the last 324 amino acids of the protein are lost. Functional studies indicate that the Q53X variant results in aberrant protein function (Kim et al., 2014). This variant is not observed in large population cohorts (Lek et al., 2016). We interpret Q53X as a pathogenic variant. -
BLEPHAROPHIMOSIS, PTOSIS, AND EPICANTHUS INVERSUS, TYPE I Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at